Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.

导出 OA

翻译打印收藏纠错

作者： Xiao,Li ^[1] ; Lander,Willem ^[2] ; Marina,Antillon ^[2] ; Joke,Bilcke ^[3] ; Mark,Jit ^[4] ; Philippe,Beutels ^[2]

作者单位： Centre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, Antwerp, Belgium. xiao.li@uantwerpen.be. ^[1] Centre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, Antwerp, Belgium. ^[2] Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel, Switzerland. ^[3] University of Basel, Petersplatz 1, Basel, Switzerland. ^[4] Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, Bloomsbury, London, UK. ^[5]

关键词 Cost-effectiveness analysis Disease burden Expected Value of Partially Perfect Information Low-income countries and lower-middle-income countries Maternal vaccination Monoclonal antibody Probabilistic sensitivity analysis Respiratory syncytial virus

主题词儿童, 学龄前(Child, Preschool);患病代价(Cost of Illness);费用效益分析(Cost-Benefit Analysis);人类(Humans);婴儿(Infant);呼吸道合胞体病毒感染(Respiratory Syncytial Virus Infections);呼吸道合胞病毒(Respiratory Syncytial Viruses)

DOI 10.1186/s12916-020-01537-6

PMID 32248817

发布时间 2020-09-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交